Safety review of oral bisphosphonates continues
Links shared publicly online about this topic.
- 130total visits
Safety review of oral bisphosphonates continues
View full resource at endocrinetoday.com
Most Recently Shared on July 21, 2011 at 5:46 pm By:
Safety review of oral #bisphosphonates continues http://bit.ly/o6Mods
SAFETY ALERT: Bisphosphonates May Increase Esophageal Cancer Risk - MPR
empr.com — “The FDA has notified healthcare professionals that it is performing a review of data from published studies to evaluate if oral bisphosphonate drugs are associated with an increased risk of cancer of the esophagus.” View full resource at empr.com
Most Recently Shared on July 21, 2011 at 7:19 pm By:
MPR News: SAFETY ALERT: Bisphosphonates May Increase Esophageal Cancer Risk: The FDA has notified healthcare pro... http://bit.ly/pYZyDJ
Safety review of oral bisphosphonates continues | HemOncToday
hemonctoday.com — “According to a statement released today, the FDA will continue to review data from published studies to evaluate whether use of oral bisphosphon” View full resource at hemonctoday.com
Most Recently Shared on July 21, 2011 at 5:49 pm By:
HemOnc Today Oncology and Health News
#FDA continues to review data on oral bisphosphonate–cancer link http://bit.ly/qYl5Px
FDA Drug Safety Communication: Ongoing safety review of oral osteoporosis drugs (bisphosphonates) and potential increased risk of esophageal cancer
fda.gov — “[07-21-2011] The U.S. Food and Drug Administration (FDA) is continuing to review data from published studies to evaluate whether use of oral bisphosphonate drugs is associated with an increased risk of cancer of the esophagus (esophageal cancer).” View full resource at fda.gov
Most Recently Shared on July 21, 2011 at 3:39 pm By:
elaine schattner Oncologist, Hematologist, Physician, Doctor, and Internist
FDA reviewing safety of osteoporosis drugs for possible risk of esophageal cancer - http://1.usa.gov/r4qwFG
MedWire News - General Practice - GPs to review bisphosphonate use
medwire-news.md — “MedWire News GPs should review the need to continue bisphosphonate use, particularly in patients who have been taking one for 5 or more years, updated safety advice indicates. MedWire News” View full resource at medwire-news.md
Most Recently Shared on June 23, 2011 at 2:17 pm By:
FDA Alert: Oral Bisphosphonates: Ongoing Safety Review of Atypical Subtrochanteric Femur Fractures
drugs.com — “FDA Alert: Oral Bisphosphonates: Ongoing Safety Review of Atypical Subtrochanteric Femur Fractures” View full resource at drugs.com
Most Recently Shared on March 14, 2010 at 12:56 am By:
RT @drugscom FDA Alert: Oral Bisphosphonates: Ongoing Safety Review of Atypical Subtrochante.. http://tinyurl.com/yefqn4x
FDA Alert: Oral Bisphosphonates: Ongoing Safety Review of Atypical Subtrochanteric Femur Fractures
drugs.com — “FDA Alert: Oral Bisphosphonates: Ongoing Safety Review of Atypical Subtrochanteric Femur Fractures” View full resource at drugs.com
Most Recently Shared on March 13, 2010 at 9:31 am By:
FDA Alert - Oral Bisphosphonates: Ongoing Safety Review - http://bit.ly/9EfpXY
Oral Bisphosphonates: Ongoing Safety Review of Atypical Subtrochanteric Femur Fractures
fda.gov — “FDA review of available data have not shown a clear connection between bisphosphonate use and a risk of atypical subtrochanteric femur fractures.” View full resource at fda.gov
Most Recently Shared on March 11, 2010 at 9:41 pm By:
eyeonfda Pharma and Health Lawyer
MedWatch Alert just posted on FDA site for Oral Bisphosphonates - http://ow.ly/1hmu4
FDA Drug Safety Communication: Ongoing safety review of oral bisphosphonates and atypical subtrochanteric femur fractures
fda.gov — “FDA Drug Safety Communication: Ongoing safety review of oral bisphosphonates and atypical subtrochanteric femur fractures” View full resource at fda.gov
Most Recently Shared on March 10, 2010 at 7:33 pm By:
Najeh Ahmad, MD MPH Family Medicine Doctor, Physician, and Doctor
FDA take on #osteoporosis meds (like: #fosamax, #actonel, #boniva) causing atypical hip #fractures with long term use http://bit.ly/Bisphos
Advertisement
